AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25880814 — intervention group
Group type: EXPERIMENTAL
Intervention: OXCAP-RT (oxaliplatin 85 mg/m2 Day 1,15,29; capecitabine 625 mg/m2 twice daily on days of RT; RT-45 Gy/25 fractions/5 weeks)
Number of subjects: 76
Study 25880814 — intervention group
Group type: COMPARATOR
Intervention: CarPac-RT (Carboplatin AUC2 and paclitaxel 50 mg/m2 Day 1,8,15,22,29; RT-45 Gy/25 fractions/5 weeks)
Number of subjects: 76
Study 25880814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OXCAP-RT and CarPac-RT
Number of subjects: 76
Study 23674855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (N. sativa) administered for three months at a dose of 450 mg three times daily
Number of subjects: 30
Study 21270583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal buffered lidocaine
Number of subjects: 148
Study 21270583 — intervention group
Group type: COMPARATOR
Intervention: Intradermal bacteriostatic normal saline
Number of subjects: 148
Study 19207871 — intervention group
Group type: EXPERIMENTAL
Intervention: Short vaccination protocol: 20 microg i.m. once a week for 8 weeks
Number of subjects: 51
Study 19207871 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination protocol: three doses of 40 microg i.m. at months 0, 1 and 6
Number of subjects: 51
Study 19207871 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination protocol
Number of subjects: 51
Study 16952539 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness plication
Number of subjects: 159
Study 16952539 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 159
Study 15032280 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (TP)
Number of subjects: 18
Study 15032280 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/cyclophosphamide (CP)
Number of subjects: 18
Study 11733887 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with stroke
Number of subjects: 19
Study 11733887 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 19
Study 8602592 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) 1000 mg/d
Number of subjects: 20
Study 8602592 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) 1000 mg/d plus 5 micrograms (200 IU) vitamin D/d
Number of subjects: 20
Study 8602592 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (1 L more than usual daily diet)
Number of subjects: 20
Study 8602592 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (three tablets daily)
Number of subjects: 20
Study 1548922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical anastomosis
Number of subjects: 60
Study 1548922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic anastomosis
Number of subjects: 60
Study 1548922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal esophagectomy
Number of subjects: 60
Study 2865502 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min
Number of subjects: 129
Study 2865502 — intervention group
Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 129
Study 2865502 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 129
Study 30919515 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking)
Number of subjects: 8
Study 30919515 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking) at matched ventilations
Number of subjects: 8
Study 30919515 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking) at 100% V̇E,UBE
Number of subjects: 8
Study 30231777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 27228564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 40
Study 27228564 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach (non-US guidance)
Number of subjects: 40
Study 24343325 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 repetition maximum (RM) squat followed by countermovement jump (CMJ)
Number of subjects: 22
Study 24343325 — intervention group
Group type: COMPARATOR
Intervention: Control group performed CMJ at 15 seconds and at 4, 8, 12, 16, and 20 minutes
Number of subjects: 22
Study 22328280 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling-like alternative (low probability, high payoff)
Number of subjects: 0
Study 22328280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory depletion manipulation
Number of subjects: 0
Study 22328280 — intervention group
Group type: COMPARATOR
Intervention: Absence of gambling activity
Number of subjects: 0
Study 20926016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day for 4 weeks
Number of subjects: 42
Study 20926016 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐placebo, non‐treatment)
Number of subjects: 42
Study 19001742 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP 200 mg/kg infused intravenously before anesthesia
Number of subjects: 106
Study 19001742 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose infusion (control group)
Number of subjects: 106
Study 19001742 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP 200 mg/kg
Number of subjects: 106
Study 16380703 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 85
Study 16380703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor-I (IGF-I)
Number of subjects: 85
Study 16380703 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
Number of subjects: 85
Study 16380703 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index (PASI)
Number of subjects: 85
Study 16380703 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Healthy Persons)
Number of subjects: 85
Study 12417879 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDI (0 to 576 microg)
Number of subjects: 15
Study 12417879 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDI (90 microg and 180 microg)
Number of subjects: 15
Study 12417879 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDI
Number of subjects: 15
Study 10599545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/hMG
Number of subjects: 324
Study 10599545 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist/hMG
Number of subjects: 324
Study 7547766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (0.625 mg conjugated equine oestrogens with 0.15 mg cyclic norgestrel for 12 days per 28 day cycle)
Number of subjects: 33
Study 7547766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1437059 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole troches, 10 mg, five times daily
Number of subjects: 34
Study 1437059 — intervention group
Group type: COMPARATOR
Intervention: Nystatin suspension, 500,000 units, four times daily
Number of subjects: 34
Study 3980803 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylpsoralen bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (1 mg/kg/day)
Number of subjects: 25
Study 3980803 — intervention group
Group type: COMPARATOR
Intervention: Bath PUVA
Number of subjects: 25
Study 3980803 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (1 mg/kg/day)
Number of subjects: 25
Study 3980803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA (maintenance therapy)
Number of subjects: 25
Study 3980803 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (25‐50 mg daily)
Number of subjects: 25
Study 30019357 — intervention group
Group type: EXPERIMENTAL
Intervention: Masticatory muscle stretching exercises for 10 days
Number of subjects: 24
Study 30019357 — intervention group
Group type: COMPARATOR
Intervention: Control group (received sleep hygiene advice only)
Number of subjects: 24
Study 28228411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVZ)
Number of subjects: 61
Study 28228411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant (DEX)
Number of subjects: 61
Study 23271686 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic suturing instrument (Group 2)
Number of subjects: 1464
Study 23271686 — intervention group
Group type: COMPARATOR
Intervention: Deschamps ligature carrier (Group 1)
Number of subjects: 1464
Study 21854488 — intervention group
Group type: EXPERIMENTAL
Intervention: PIV cannulation with the VeinViewer (VV)
Number of subjects: 323
Study 21854488 — intervention group
Group type: COMPARATOR
Intervention: Standard PIV cannulation (SC)
Number of subjects: 323
Study 19028519 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment-focused website
Number of subjects: 106
Study 19028519 — intervention group
Group type: COMPARATOR
Intervention: Motivational-information website
Number of subjects: 106
Study 17910218 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (CP)
Number of subjects: 20
Study 17910218 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (CP) with potassium nitrate and fluoride (PF)
Number of subjects: 20
Study 12764624 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (2x850 mg/day for 8 weeks)
Number of subjects: 32
Study 12764624 — intervention group
Group type: COMPARATOR
Intervention: Control group (only gonadotropin induction)
Number of subjects: 32
Study 11527172 — intervention group
Group type: EXPERIMENTAL
Intervention: Inchin‐ko‐to (ICKT) 0.15 g/kg per day administered orally for 1 year
Number of subjects: 18
Study 9283530 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intraaortic balloon counterpulsation (IABP) within one calendar day of enrollment
Number of subjects: 310
Study 9283530 — intervention group
Group type: COMPARATOR
Intervention: No intraaortic balloon counterpulsation (IABP) (insertion on or after day 2 or never)
Number of subjects: 310
Study 7920930 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down protocol (FSH +/‐ hMG without LHRH agonist)
Number of subjects: 26
Study 7920930 — intervention group
Group type: COMPARATOR
Intervention: Step-up protocol (FSH +/‐ hMG without LHRH agonist)
Number of subjects: 26
Study 7920930 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down protocol (FSH +/‐ hMG with LHRH agonist)
Number of subjects: 26
Study 7920930 — intervention group
Group type: COMPARATOR
Intervention: Step-up protocol (FSH +/‐ hMG with LHRH agonist)
Number of subjects: 26
Study 3532967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 5 mg/kg daily
Number of subjects: 20
Study 3532967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3532967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 20
Study 29407633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 50
Study 29407633 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant (control)
Number of subjects: 50
Study 27160844 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT) combined with cognitive-behavioural group aftercare (AC) for 12 weeks and 4 weeks respectively.
Number of subjects: 0
Study 25200640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 78
Study 25200640 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 78
Study 25200640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 78
Study 22747652 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived drug treatment
Number of subjects: 36
Study 22747652 — intervention group
Group type: COMPARATOR
Intervention: Perceived placebo treatment
Number of subjects: 36
Study 20585224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 124
Study 18842969 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented intervention by a practice nurse
Number of subjects: 900
Study 18842969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient-oriented intervention)
Number of subjects: 900
Study 18842969 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented intervention
Number of subjects: 900
Study 18842969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study 15869544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) applied once daily
Number of subjects: 26
Study 15869544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) applied on alternate days
Number of subjects: 26
Study 15869544 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial once-daily followed by alternate-day application
Number of subjects: 26
Study 15869544 — intervention group
Group type: COMPARATOR
Intervention: Control site with vehicle application
Number of subjects: 26
Study 12693197 — intervention group
Group type: EXPERIMENTAL
Intervention: Training phase with sequences of letters generated by a finite-state grammar
Number of subjects: 0
Study 12693197 — intervention group
Group type: COMPARATOR
Intervention: Control group responding to randomized sequences
Number of subjects: 0
Study 10595053 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls
Number of subjects: 78
Study 10595053 — intervention group
Group type: COMPARATOR
Intervention: Standard post-discharge care
Number of subjects: 78
Study 8712437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0% end-tidal concentration
Number of subjects: 8
Study 8712437 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 0.85% end-tidal concentration
Number of subjects: 8
Study 8712437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.55% and 0.7% end-tidal concentrations
Number of subjects: 8
Study 1934546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 0
Study 1934546 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum
Number of subjects: 0
Study 7253867 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE)
Number of subjects: 728
Study 7253867 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE)
Number of subjects: 728
Study 30994371 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding cessation reasons
Number of subjects: 221
Study 30994371 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 221
Study 30994371 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning to work/school
Number of subjects: 221
Study 28767570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5mg (5mL)
Number of subjects: 80
Study 28767570 — intervention group
Group type: COMPARATOR
Intervention: Morphine hydrochloride 5mg (5mL)
Number of subjects: 80
Study 26010029 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuCirc
Number of subjects: 150
Study 26010029 — intervention group
Group type: COMPARATOR
Intervention: Mogen clamp
Number of subjects: 150
Study 25702400 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinine (ALP) (1.5 mg/kg/d)
Number of subjects: 73
Study 25702400 — intervention group
Group type: COMPARATOR
Intervention: Quinidine bisulphate (QUIN) (15 mg/kg/d)
Number of subjects: 73
Study 25702400 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinine (ALP)
Number of subjects: 73
Study 25702400 — intervention group
Group type: COMPARATOR
Intervention: Quinidine bisulphate (QUIN)
Number of subjects: 73
Study 22215166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2010
Study 22215166 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2010
Study 18922712 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections of <0.5 ml 1% polidocanol foam
Number of subjects: 107
Study 18922712 — intervention group
Group type: COMPARATOR
Intervention: Few injections of >0.5 ml 1% polidocanol foam
Number of subjects: 107
Study 18922712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 17278196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg b.i.d.)
Number of subjects: 607
Study 17278196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (b.i.d.)
Number of subjects: 607
Study 15361727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 30 mg/kg/day b.i.d. for 5 days
Number of subjects: 626
Study 15361727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 15 mg/kg/day b.i.d. for 5 days
Number of subjects: 626
Study 15361727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate 43.8/6.2 mg/kg/day b.i.d. for 5 days
Number of subjects: 626
Study 15361727 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 30 mg/kg/day 3 times a day for 10 days
Number of subjects: 626
Study 11603222 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of progesterone
Number of subjects: 107
Study 11603222 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of progesterone
Number of subjects: 107
Study 11603222 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of progesterone
Number of subjects: 107
Study 11603222 — intervention group
Group type: COMPARATOR
Intervention: Estrogen only (control)
Number of subjects: 107
Study 11603222 — intervention group
Group type: EXPERIMENTAL
Intervention: Late secretory endometrium from 19 premenopausal women
Number of subjects: 107
Study 9658047 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulus to the superficial peroneal nerve during walking
Number of subjects: 0
Study 8080744 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening (7 years)
Number of subjects: 22294
Study 8080744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 22294
Study 2787887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol (30 micrograms/day)
Number of subjects: 2
Study 2787887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 178687 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic E administration (ethinyl estradiol 0.5 mg/day for 7 to 70 days)
Number of subjects: 6
Study 178687 — intervention group
Group type: EXPERIMENTAL
Intervention: iv administration of E (bolus injection of 25 mg conjugated estrogens, USP)
Number of subjects: 6
Study 178687 — intervention group
Group type: COMPARATOR
Intervention: iv administration of normal saline
Number of subjects: 6
Study 30879954 — intervention group
Group type: EXPERIMENTAL
Intervention: Primene (n=14)
Number of subjects: 94
Study 30879954 — intervention group
Group type: COMPARATOR
Intervention: TrophAmine (n=21)
Number of subjects: 94
Study 30879954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study 27771320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water injections (SWI)
Number of subjects: 9
Study 25825373 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional alar base cinching
Number of subjects: 60
Study 25825373 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified alar base cinching
Number of subjects: 60
Study 23760911 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 54
Study 23760911 — intervention group
Group type: COMPARATOR
Intervention: labetalol
Number of subjects: 54
Study 21196807 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based program for PD with DSI
Number of subjects: 123
Study 21196807 — intervention group
Group type: COMPARATOR
Intervention: Long-term residential program for PD with DSI
Number of subjects: 123
Study 18714500 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane treatment
Number of subjects: 0
Study 17174180 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 436
Study 17174180 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 436
Study 14519795 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet (% of energy: CHO, 58.3; fat, 25.8)
Number of subjects: 65
Study 14519795 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid (MUFA) diet (% of energy: CHO, 44.7; fat, 40.1; MUFA, 22.5)
Number of subjects: 65
Study 14519795 — intervention group
Group type: COMPARATOR
Intervention: High MUFA diet
Number of subjects: 65
Study 11117099 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-present condition (familiar letter paired with a novel letter containing a distinguishing element)
Number of subjects: 60
Study 11117099 — intervention group
Group type: COMPARATOR
Intervention: Feature-absent condition (familiar letter paired with a novel letter with one element removed)
Number of subjects: 60
Study 11117099 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization time of 20 seconds
Number of subjects: 60
Study 11117099 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization time of 30 seconds
Number of subjects: 60
Study 8781870 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms, four puffs)
Number of subjects: 15
Study 8781870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1290334 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload-Cu375 (MLCu375)
Number of subjects: 0
Study 1290334 — intervention group
Group type: COMPARATOR
Intervention: Multiload-Cu250 (MLCu250)
Number of subjects: 0
Study 6611385 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim and sulfamethoxazole
Number of subjects: 67
Study 30712496 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion lignocaine
Number of subjects: 19
Study 26656722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-thrombolysis (IV rt-PA administration in ER)
Number of subjects: 49
Study 26656722 — intervention group
Group type: COMPARATOR
Intervention: Usual care (immediate transfer to stroke center)
Number of subjects: 49
Study 27062408 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 0.025 mg BID
Number of subjects: 224
Study 27062408 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 0.05 mg BID
Number of subjects: 224
Study 27062408 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 0.1 mg BID
Number of subjects: 224